Document:

Exclusive Distribution Agreement

 Exhibit 10.1 
 *** Text Omitted and Filed Separately 
 Confidential Treatment Requested 

Under 17 C.F.R. §§ 200.80(b)(4) and 17 C.F.R. 24b-2 
 EXCLUSIVE DISTRIBUTION AGREEMENT 
 THIS
EXCLUSIVE DISTRIBUTION AGREEMENT (the “Agreement”) is made and entered into the 1st day of August, 2011 (“Effective Date”), by and between Vermillion Inc., a Delaware corporation with its principal business address
at 12117 Bee Caves Rd. Building III, Suite 100, Austin, TX 78738, USA (“Supplier”) and Pronto Diagnostics Ltd., an Israeli company with registered address at 19a Habarzel St., Ramat Hachayal, Tel Aviv 69710, Israel
(“Distributor”). 
 NOW, THEREFORE, the parties agree as follows: 

 

	1.	Definitions 

 Test:
OVA1 Test. 
 Territory: Israel and areas under Palestinian control 

Software: the software and any update, upgrade, improvement or new version thereto, provided by Supplier to Distributor in
connection with the Test, all as required for the interpretation of the results of the Test for each sample. 
 HMOs:
Israeli health maintenance organizations. 
  

	2.	Scope of Appointment 

  

	 	a.	Distributor is appointed as exclusive distributor for the Test in the Territory during the Term (as defined below) and Supplier shall neither sell nor otherwise be
commercially involved with selling Tests in the Territory, nor appoint any distributor or other representative in the Territory with respect to the Tests during the Term. If Supplier will wish to sell or otherwise commercialize future variations or
versions of the Test, Distributor would be first offered by Supplier to receive exclusive rights to distribute, use and sell those Tests on mutually agreeable terms in the Territory, provided the Distributor has proven to be successful in launching
the first Test. 

  

	 	b.	Distributor may solicit and procure Orders (as defined below) only within the Territory and shall not otherwise solicit orders for the Test or act as the
Supplier’s distributor or representative with respect to any other territories. Nothing in this Agreement shall be construed as limiting in any manner Supplier’s marketing or distribution activities or its appointment of other dealers,
distributors, licensees, agents or representatives of any kind outside the Territory, provided that Supplier shall sell or provide the Tests and/or the Software outside the Territory only under binding agreements that do not permit the sale or
distribution of the Tests in the Territory. The Supplier shall refer any commercial inquiries regarding the Test in the Territory to Distributor. 

	 	c.	Each party hereby represents, warrants and covenants that the execution, delivery, and performance of this Agreement in accordance with its terms will not result in any
violation of any agreement or instrument to which it is a party. Distributor hereby represents and warrants to Supplier that it will comply with all applicable laws of the Territory in its performance of its obligations contemplated by this
Agreement and that the execution, delivery, and performance of this Agreement in accordance with its terms will not result in any violation of any law of the Territory. 

 

	3.	Orders 

  

	 	a.	Distributor shall promote and solicit orders for the Test in the Territory (each, an “Order”) and otherwise provide reasonable assistance and support to its
customers. 

  

	 	b.	Distributor shall determine within two (2) months after the Effective Date whether regulatory approval and/or registration are required for the Test. If any such
regulatory approval and/or registration are required for the Test, Distributor shall use commercial reasonable efforts to promptly obtain such regulatory approval and/or registration, as applicable. 

 

	 	c.	In order to maintain the exclusivity of its appointment as distributor under this Agreement, Distributor shall provide commercial reasonable efforts to sell a minimum
of [***] Tests in the first year following regulatory approval and registration of OVA1 in Israel (if and to the extent required), or the date upon which it is determined as per subsection (b) above by Distributor that no regulatory approval
and/or registration are required for the Test, as applicable (such date, the “Minimum Test Start Date”). For any years of the Term following the first anniversary of the Minimum Test Start Date, the parties will discuss (over the
last 30 days of each prior year) the minimum quantities for the upcoming year. If the parties cannot agree on minimum quantities by the end of each such prior year, Supplier shall have the right, exercisable in its sole discretion, to terminate, the
exclusivity of Distributor’s appointment under this Agreement, subject to a thirty (30) days prior written notice. 

 [***] 
  

	 	d.	 Supplier hereby represents and warrants to Distributor that (i) Supplier owns exclusive title and ownership to the Test and the Software and owns
(or will own prior to release to Distributor) any updates, upgrades, improvements, inventions, patent rights, trade secrets, know-how in connection therewith; (ii) Supplier has the right to provide the Test and the Software to Distributor for
purposes of selling same to Distributor’s customers and/or for the purpose of carrying out the Test; and (iii) that the Test, the Software and any results generated therewith, and any trademark, trade name or other names, signs or marks
used in connection thereto (the “Marks”), to Supplier’s knowledge, do not and will not infringe the rights of any third party, including, but not limited to proprietary rights and intellectual property rights. Supplier
shall defend and hold Distributor harmless from and against any claims of any third party that the Software infringes any intellectual property right (unless such claims result from the breach by Distributor of its obligations under

	 	
Section 7 below); provided, however, that Supplier is promptly given the right to defend such claims with counsel reasonably satisfactory to Distributor, that Supplier may not settle any
such claim or suit without Distributor’s specific prior agreement and consent in writing if the settlement is not merely financial, and that Distributor assists and cooperates to the extent reasonably requested by Supplier.

  

	4.	Fees. 

  

	 	a.	In consideration for the performance of all of Supplier’s obligations under this Agreement (including but without limitation in connection with the Software and
the approval of reagents’ lots as further detailed below), Distributor shall pay to Supplier on or before the fifteenth (15th) day of each quarter for all Tests performed during the preceding quarter at the following rate: a royalty equal
to [***] percent ([***]%) of the amounts invoiced by Distributor to its customers with respect to the Tests during the preceding quarter (VAT excluded) but in no event less than the following applicable minimum amount per Test performed during the
quarter: 

  

	 	i.	US$[***]/Test with respect to customers for which Distributor reasonably expects to sell fewer than [***] ([***]) Tests per year (excluding HMO).

  

	 	ii.	US$[***]/Test for any other customers (excluding HMO). 

  

	 	iii.	In special cases, and with respect to deals with one of the four HMOs, the parties will mutually agree on special minimum royalty amounts which shall not be lower than
US$[***]/Test. 

  

	 	b.	The list price recommended by Supplier for sale of the Test to Distributor’s customers is to be [***] US dollars per Test (US$[***]/test) plus VAT, to the extent
applicable, however Distributor will have sole discretion to set the prices of the Test for its customers and for collecting payment from its customers. It is further clarified that HMOs will likely reimburse (and pay) at a lower level than the list
price; however, the foregoing shall still apply. 

  

	 	c.	Payment will be made by a wire in US funds within fifteen (15) days after the end of each fiscal quarter. Payment will be accompanied by a reconciliation of the
payment amount to determine how it was calculated. Distributor will be responsible for paying all withholding taxes in the Territory. 

  

	 	d.	Supplier will have customary audit rights on the reconciliation and reimbursement amount at its discretion upon reasonable coordination with Distributor and access to
any other information reasonably requested related to the Test sales, sales and marketing activities or related efforts. 

  

	5.	Responsibilities of Distributor. 

 Distributor shall: 
  

	 	a.	 Act for the registration of OVA1 with the Israeli Ministry of Health under the name of Supplier, which registration, along with any and all other

	 	
licenses, permits, authorizations or approvals obtained under this Agreement, shall be the property of Supplier, all if and to the extent permitted under any applicable law; if registration will
require a clinical trial the division of labor and expenses will be [***]% of costs to Supplier, [***]% of the costs to Distributor. 

  

	 	b.	Provide marketing plan and sales projections within sixty (60) days of signing this agreement. 

 

	 	c.	Cause its marketing and sales force to utilize commercially reasonable efforts to promote and sell the Test in the Territory and to reasonably maximize sales thereof.

  

	 	d.	Be responsible for carrying out the Test (and purchasing all required instrumentation, reagents, and service contracts) in its own lab and/or in one or more third-party
labs approved by Supplier in the Territory in accordance with the Test insert and applicable regulatory requirements, and to provide the Software to such third party labs. 

 

	 	e.	Arrange for translation of the Test insert into the required language for use in its laboratories. 

 

	 	f.	Provide promptly any data to Supplier which reasonably requests and to which Distributor reasonably has access, including without limitation the following data on a
monthly basis: 

  

	 	i.	a count of Tests performed by all of its laboratories using the reporting function in OVACalc. 

 

	 	ii.	specific payor type (i.e., private pay, HMO, government, etc.) for each Test performed. 

 

	 	iii.	additionally, when the Test is carried out by Distributor, Distributor will also provide the following data: 

 

	 	1.	ordering physician’s name and place for each Test performed, and 

  

	 	2.	invoiced amount for each Test performed. 

  

	 	g.	Use Supplier’s name and Supplier’s then-current names for the Test in its marketing and promotional efforts and materials, all of which marketing and
promotional efforts and materials are subject to Supplier’s reasonable prior approval, and not add to, supplement, delete from or modify any sales or marketing documentation or forms or representations provided by Supplier except with the prior
written consent of Supplier, or make any representations or warranties regarding the Test on behalf of Supplier or itself other than those specified in Attachment A hereto and/or explicitly authorized by Supplier in writing, including the
materials provided in accordance with Section 6(d). 

  

	 	h.	Not market, promote, sell or solicit orders for or otherwise represent any test in competition with the Test. 

 

	 	i.	Comply with all applicable laws and orders in the Territory in its performance of its obligations under this Agreement. 

	6.	Certain Responsibilities of Supplier. 

 Supplier shall, for no additional charge: 
  

	 	a.	Train Distributor to run the Test and Software, educate Distributor on a continuing basis with updated scientific and marketing related information relevant to the
Test, and provide support to Distributor’s staff as reasonably requested, so as to allow it to provide its customers with updated and accurate information regarding the Test and its possible use in clinical practice. 

 

	 	b.	Administer the proficiency test to all the labs reasonably proposed by Distributor for conducting the Test. 

 

	 	c.	Approve reagent lots on an on-going basis and provide a listing of approved reagent lots to Distributor for performance of the Test. 

 

	 	d.	Provide reasonable market development assistance and materials. These materials will include such items as peer reviewed articles, committee opinions, clinical papers,
etc. Nothing in this Section 6(d) obligates, or shall be deemed as obligating, Supplier to create or have created any such materials outside of its normal course of business in its sole discretion. 

 

	 	e.	Participate in marketing related events that Distributor will organize in the Territory as workshop or lecture at major conferences (maximum of 2 times/yr).

  

	 	f.	Provide to Distributor (i) the Software and other means required for data analysis, and keep Distributor up-to-date with Software upgrades and new Software
releases; (ii) support with respect to Software bugs and/or malfunctions; and (iii) reasonable customization, modifications and/or extension of the Software for the purpose of implementation of the Software with Distributor’s
customers. 

  

	7.	Trademarks and Software. 

Subject to the terms of this Agreement, Supplier grants Distributor the nonexclusive, limited, non-transferrable, revocable and
non-sublicensable right (a) to use and display the Marks during the Term in any sales or marketing materials developed by Distributor; (b) to use the Software for the purposes set forth in this Agreement; and (iii) to provide the
Software to labs authorized by Supplier as per Section 6(b) above and subject to a royalty free license agreement in the form reasonably agreed to by Supplier (such agreement to include an indemnification clause according to which such lab
shall indemnify and hold Supplier and Distributor harmless from any claim and/or demand resulting from such lab’s act or omission, it being understood that should Supplier not be able to negotiate such terms with a particular lab, Distributor
shall propose another lab). Distributor will not use, register or take other action with respect to any Mark or the Software except to the extent authorized in advance in writing by Supplier, and, with respect to the Software (or any part thereof),
agrees not to modify, revise, create derivative works or otherwise make any derivative uses; decompile, reverse engineer or otherwise attempt to derive the source code; or otherwise use for other than its intended purpose. No other intellectual
property rights or licenses to the Marks, Software, Test or otherwise are being transferred hereunder, whether expressly, by implication, estoppel or otherwise, and Distributor acknowledges that all other rights, title and interest to the Marks,
Software and Tests are and shall remain with Supplier. 

	8.	Term and Termination. 

This Agreement shall be in full force and effect commencing with the Effective Date and for a period of [***] years following the Minimum
Test Start Date, and may be renewed upon the mutual agreement of the parties for additional periods of [***] each (collectively, the “Term”). 
 Notwithstanding the above, if either party materially breaches this Agreement and such breach continues for a period of thirty (30) days after receipt by the breaching party of a written notice
thereof, the other party may immediately terminate this Agreement. This Agreement may also be terminated by Supplier (a) upon the expiration of thirty days (30) prior written notice to Distributor for any of the following events which have
not been resolved during such notice period: (i) if Distributor shall fail to secure or renew any license, permit, authorization or approval for the conduct of its business in any significant area of the Territory, or if any such license,
permit, authorization or approval is revoked or suspended; (ii) upon the institution by or against Distributor of insolvency, receivership or bankruptcy proceedings; or (iii) if Distributor breaches any of its material representations,
warranties or covenants under this Agreement, including without limitation those set forth in Sections 5(f) and 5(j); or (b) immediately if Distributor ceases to do business for more than thirty (30) days. 

Upon termination or expiration of this Agreement for any reason whatsoever, (i) Distributor shall immediately
discontinue any use of the Marks, (ii) Distributor will cease to promote or solicit orders for the Test, and (iii) each party will promptly return to the other party (or, at such other party’s sole discretion, destroy) all Proprietary
Information (as defined below) of the other party, and Distributor will promptly return to Supplier (or, at Supplier’s sole discretion, destroy) all of Distributor’s copies of the Software and will use commercial reasonable efforts to
return to Supplier all copies of the Software distributed to labs as per Section 6(b) above. Notwithstanding the foregoing, the last sentence of Section 4, Section 5.g, the second sentence of Section 7, and Sections 9-11, 12, 14
and 15 and the obligation of Distributor to deliver to Supplier payments for Tests performed prior to termination or expiration, shall survive termination or expiration of this Agreement. 

 

	9.	Proprietary Rights. 

 Each
party acknowledges that, in the course of performing its duties under this Agreement, it may obtain business, technical or financial information of or relating to the other party, all of which is confidential and proprietary (“Proprietary
Information”). The receiving party and its employees and agents shall, at all times, both during the Term and after its termination, keep in trust and confidence all such Proprietary Information (including for the removal of doubt the
financial terms of this Agreement), and shall not use such Proprietary Information other than in the course of its duties as expressly provided in this Agreement; nor shall the receiving party or its employees or agents disclose any such Proprietary
Information to any person without the disclosing party’s prior written consent. The receiving party shall not be bound by this Section with respect to information it can document has entered or later enters the public domain as a result of no
act or omission of the receiving party, or is lawfully 

 
received by the receiving party from third parties without restriction and without breach of any duty of nondisclosure by any such third party, is independently developed be the receiving party
or must be disclosed pursuant to a court order, or as required by any governmental or administrative authority or regulatory agency. Distributor acknowledges and agrees that Supplier owns all right, title and interest in and to the Test and Software
and all related Proprietary Information, documentation, sales and marketing materials, and all Marks, as well as all intellectual property rights related to the foregoing and including any updates to the foregoing. 

 

	10.	Indemnification. 

  

	 	a.	Distributor agrees to indemnify, defend and hold harmless Supplier and its employees, officers, directors and agents from and against any and all damages, liabilities,
costs and expenses (including reasonable attorneys fees and court costs) incurred by Supplier in a final award by a competent authority as a result from: (a) Distributor’s breach of any of its representations, warranties or covenants under
this Agreement, including without limitation Section 5(j); and/or (b) Distributor’s fraud, bad faith or gross negligence with respect to this Agreement or its performance hereunder; provided, however, that Distributor is
promptly given the right to defend such claims with counsel reasonably satisfactory to Supplier, that Distributor may not settle any such claim or suit without Supplier’s specific prior consent in writing if the settlement is not merely
financial, and that Supplier assists and cooperates to the extent reasonably requested by Distributor. 

  

	 	b.	 Supplier shall indemnify, defend and hold harmless Distributor and its employees, officers, directors and agents from and against any and all damages,
liabilities, costs and expenses (including reasonable attorneys fees and court costs) incurred by Distributor in a final award by a competent authority as a result of (a) the breach by Supplier of any representation, warranty, covenant or
obligations contained in this Agreement, and/or (b) any claim, action, demand or proceeding brought against the Distributor in connection with the Test, the Software and/or the reagents, to the extent such claim, action, demand or proceeding is
solely due to a defect or error in the Test and/or the Software supplied by Supplier and/or the reagents authorized by Supplier, and to the extent not caused by Distributor or any third party (including without limitation any labs) not under control
of Supplier, including without limitation by any breaches of the terms of this Agreement by Distributor or any such third party, any failure by Distributor to comply completely with written instructions or documentation issued by Supplier to
Distributor or such third party, any mishandling of the Test, Software and/or reagents by Distributor or any such third party, or any combination, modification or alteration of the Test, Software and/or reagents with any other materials or services
by Distributor or any such third party, and/or (c) as provided in Section 3(d)(iii) above, provided, however, that Supplier is promptly given the right to defend such claims with counsel reasonably satisfactory to Distributor, that
Supplier may not settle any such claim or suit without Distributor’s specific prior consent in writing if the settlement is not merely financial, and that Distributor assists and cooperates to the extent reasonably requested by Supplier. For
clarification, in the event of any 

	 	
claim, action, demand or proceeding brought against the Distributor and due only in part to any defect or error in the Test and/or the Software supplied by Supplier and/or the reagents authorized
by Supplier, nothing contained herein shall be construed as derogating from Supplier’s liability to indemnify Distributor with respect to such Supplier’s part, subject to all the terms and conditions of this Agreement. 

  

	 	c.	Notwithstanding the foregoing, Suppler and Distributor understand that such items that would reasonably be considered to be “de minimis” shall not be subject
of this Section 10. 

  

	11.	Limitation of Liability. 

Except with respect to claims relating to infringement of intellectual property rights, and/or to breaches of Sections 7 or 9:
(a) a party will not be liable with respect to any subject matter of this agreement or under any contract, negligence, strict liability or other legal or equitable theory for any indirect, incidental, special, punitive or consequential damages,
and (b) except indemnification of Distributor by Supplier with respect to third party claims pursuant to the terms of Section 10(b), the aggregate liability of each party and its affiliates hereunder is limited to the aggregate amounts
paid by Distributor to Supplier under this Agreement. 
  

	12.	Disclaimer of Warranty. 

SUPPLIER DOES NOT MAKE ANY WARRANTIES CONCERNING THE TEST, OTHER THAN THOSE EXPRESSLY SET FORTH IN SECTION 3.D, IN ATTACHMENT A AND
AS MAY BE PROVIDED FROM TIME TO TIME BY SUPPLIER PURSUANT TO SECTION 6.D ABOVE, AND THE TESTS ARE OTHERWISE PROVIDED “AS-IS,” WITHOUT ANY WARRANTY OF ANY KIND, WHETHER EXPRESS, IMPLIED, OR STATUTORY, INCLUDING BUT NOT LIMITED TO ANY
IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE, AS WELL AS ANY WARRANTIES ARISING FROM COURSE OF DEALING, USAGE OR TRADE PRACTICE. 
  

	13.	Force Majeure. 

 Neither
party shall be responsible for delays or failures in performance resulting from acts beyond the control of such party (including war, whether declared or not), provided however that (a) both parties use commercially reasonable efforts to
mitigate the effects of any such force majeure events on their performance under this Agreement, and (b) both parties promptly fulfill their obligations under this Agreement after such force majeure event ceases. 

 

	14.	Miscellaneous. 

  

	 	a.	A party may not assign this Agreement nor will it assign any right or obligation hereunder without the prior written consent of the other party; however, either party
may assign this agreement to a successor entity or purchaser of all or substantially all of that portion of its business to which this Agreement relates, provided that the other party’s rights under this Agreement shall not be prejudiced
thereby. Except as otherwise provided herein, this Agreement shall be binding upon and inure to the benefit of the permitted successors and assigns of the parties. 

	 	b.	If any provision of this Agreement is held to be illegal or unenforceable, that provision shall be limited or eliminated to the minimum extent necessary so that this
Agreement shall otherwise remain in full force and effect and enforceable. 

  

	 	c.	Except as otherwise expressly provided herein, any provision of this Agreement may be amended or waived only with the written consent of both parties.

  

	 	d.	This Agreement, including the attachments thereto which are integral part thereof, is the sole agreement between the parties with respect to the subject matter hereof
and supersedes all prior drafts, agreements or discussions between the parties with respect thereto (including but not limited to the Nonbinding Term Sheet dated June 16, 2011), which shall not be used in any manner in the interpretation of
this Agreement. 

  

	 	e.	This Agreement is not intended by the parties to constitute or create a joint venture, pooling arrangement, partnership, agency or formal business organization of any
kind. Supplier and Distributor shall be independent contractors with each other for all purposes at all times and no party shall act as or hold itself out as agent for the other, nor shall any party create or attempt to create liabilities for the
other party except to the extent expressly specified in this Agreement. 

  

	 	f.	This Agreement shall be governed by and construed under the laws of the State of New York without regard to its conflicts of law provisions, and shall not be governed
by the U.N. Convention of Contracts for the International Sale of Goods. Any dispute that cannot be resolved amicably by the parties through negotiations within sixty (60) days shall be submitted to the exclusive jurisdiction of the courts
located in New York, New York. Each party consents to service of process and the personal jurisdiction of such courts. 

  

	 	g.	This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same
instrument. 

  

	15.	Notices. 

 Notices under
this Agreement shall be in writing in the English language, transmitted by facsimile transmission or internationally recognized overnight delivery service, and deemed delivered (i) one (1) business day after transmission by facsimile where
receipt has been confirmed by facsimile transmission or (ii) when delivered to the overnight delivery service. Notices shall be addressed as follows or to such other address as a party may specify in writing to the other party: 

If to Distributor: 
 Pronto Diagnostics Ltd. 
 19a Habarzel St, Ramat Hachayal 

 Tel Aviv 69710, Israel 

Attention: Dr. Nir Navot 
 Telephone: +972.73.2126155 
 Fax: +972.73.2126144 

E-mail: nir@prontodiagnostics.com 
 If to Supplier: 
 Vermillion, Inc. 

12117 Bee Caves Rd. 
 Building III, Suite 100 
 Austin, TX 78738, USA 

Attention: President and CEO 
 Telephone: +1.512.519.0400 
 Fax: +1.512.439.6980 

E-mail: gpage@vermillion.com (with a copy to akohli@vermillion.com) 
 IN WITNESS WHEREOF, the duly authorized representatives of the parties have signed this Agreement as of the Effective Date. 

 

					
	VERMILLION, INC.	 		 	PRONTO DIAGNOSTICS LTD.
			
	 /s/ Gail. S. Page
	 		 	 /s/ Nir Navot

	Name: Gail S. Page	 		 	Name: Nir Navot
	Title:  Chairperson and CEO	 		 	Title:   CEO

  

 ATTACHMENT A 
 [Materials provided by Supplier to Distributor under separate cover.]Consulting Agreement

 Exhibit 10.2 
 CONSULTING AGREEMENT 
 This Consulting Agreement
(“Agreement”) is made and entered into as of the 17th day of June, 2011 by and between VERMILLION, INC. (the “Company”) and Bruce A. Huebner (“Consultant”). The Company desires to retain consultant as an independent
contractor to perform consulting services for the Company, and Consultant is willing to perform such services, on terms set forth more fully below. In consideration of the mutual promises contained herein, the parties hereto (the
“Parties”) agree as follows: 
  

	 	1.	SERVICES AND CONSIDERATION 

 (a) Consultant shall perform the consulting services relating to Sales, Marketing, Business Development, Corporate Strategy and other projects agreed upon by Consultant and Management, as described in
Exhibit A (the “Services”). 
 (b) The Company shall pay Consultant the compensation set forth in Exhibit
A for the performance of the Services. The Company shall also reimburse Consultant for approved reimbursable travel expenses incurred by Consultant in performing the Services pursuant to this Agreement, provided Consultant receives written
consent from an authorized agent of the Company prior to incurring any such expenses exceeding $100. Consultant (i) shall book any air travel authorized by the Company in economy or coach class and (ii) shall book all such air travel and
related accommodations through the Company’s authorized travel services provider. 
 (c) Consultant shall submit all
statements for Services and expenses on a semi-monthly basis in a form approved by the Company. The Company shall pay each such statement fifteen (15) days after receipt. 

 

	 	2.	CONFIDENTIALITY 

(a) Definition. “Confidential Information” means any information, technical, data, trade secrets or know-how that the
Company considers to be confidential or proprietary including, but not limited to, research, product plans, products, services, suppliers, customer lists and customers, prices and costs, markets, software, developments, inventions, laboratory
notebooks, processes, formulas, technology, designs, drawings, engineering, hardware configuration information, marketing, licenses, finances, compensation packages, budgets or other business information disclosed by the Company either directly or
indirectly in writing, orally or by drawings or through Consultant’s allowed observation of parts or equipment, or through creation by consultant in the course of providing the Services during the term of this Agreement. Consultant also
understands that Confidential Information includes, but is not limited to, information pertaining to any aspects of the Company’s business that is either information not known by actual or potential competitors of the Company or is proprietary
information of the Company or its customers or suppliers, whether of a technical nature or otherwise. Further, Confidential Information, as defined herein, may include, but is not limited to, information disclosed to the Company by third parties.
Confidential Information does not include information that Consultant can establish: (i) was publicly known and made generally available in the public domain prior to the time of disclosure to Consultant by the Company;

 
(ii) becomes publicly known and made generally available after the disclosure to Consultant by the Company through no wrongful action or inaction of Consultant; (iii) is in the
possession of Consultant, without confidentiality restrictions, at the time of disclosure to Consultant by the Company as shown by Consultant’s files and records immediately prior to the time of disclosure; or (iv) has been approved for
release by the Company’s prior written authorization. 
 (b) Non-Use and Non-Disclosure. Consultant will not, during
or subsequent to the term of this Agreement, use the Company’s Confidential Information for any purpose whatsoever other than the performance of the Services on behalf of the Company. Consultant will not, during or subsequent to the term of
this Agreement, disclose the Company’s Confidential Information to any third party. Consultant shall not reverse engineer, disassemble or decompile any prototypes, software or other tangible objects, that embody the Company’s Confidential
Information. Consultant further agrees to take all reasonable precautions to prevent any unauthorized disclosure of such Confidential Information including, but not limited to, having each employee of Consultant, if any, with access to any
Confidential Information, execute a non-disclosure agreement containing provisions no less favorable to the Company and protective of Confidential Information unless Consultant has received prior written approval for such action from the Company;
and in such event, Consultant shall reproduce on any such approved copies, any of Company’s proprietary rights and confidentiality notices in the same manner in which such notices were set forth in or on the original. Consultant shall
immediately notify the Company in the event of any unauthorized use or disclosure of Confidential Information. 
 (c) Former
or Concurrent Employer’s Confidential Information. Consultant agrees that Consultant will not, during the term of this Agreement, improperly use, disclose, or induce the Company to use any proprietary information or secrets of any third
party. Consultant will not bring onto the premises of the Company unpublished document or proprietary information belonging to any third party. Consultant will indemnify the Company and hold it harmless from and against all claims, liabilities,
damages and expenses, including reasonable attorneys and costs of suit, arising out of or connection with any violation or claimed violation of a third party’s rights resulting in whole or in part from the Company’s use of the work product
of Consultant under this Agreement. 
 (d) Third Party Confidential Information. Consultant recognizes that the Company
has received and in the future will receive confidential or proprietary information of third parties subject to a duty on the Company’s part to maintain the confidentiality of such information and to use it only for certain limited purposes.
Consultant agrees that Consultant owes the Company and such third parties, during the terms of the Agreement and thereafter, a duty to hold all such confidential or proprietary information in the strictest confidence and not to disclose it to any
person, firm, corporation or other entity or to use it except as necessary in carrying out the Services for the Company consistent with the Company’s agreement with such third party. 

(e) Return of Materials. All documents and other tangible objects containing or representing Confidential Information and all
copies thereof that are in the possession of Consultant shall be and remain the property of the Company, and Consultant shall promptly return such Confidential Information and all copies thereof to the Company upon termination of this Agreement or
upon the Company’s earlier request. 

	 	3.	OWNERSHIP. 

 (a)
Assignment. Consultant agrees that all copyrightable material, notes, records, drawings, designs, inventions, improvements, developments, discoveries and trade secrets (collectively, “Inventions”) conceived, made or discovered by
Consultant, solely or in collaboration with others, during the period of this Agreement that relate in any manner to the business of the Company that Consultant may be directed to undertake, investigate or experiment with, or that Consultant may
become associated with in work, investigation or experimentation in the line of business of the Company in performing the Services hereunder, are the sole property of the Company. In addition, any Inventions made by Consultant that constitute
copyrightable subject matter shall be considered “works made for hire” as that term is defined in the United States Copyright Act. Consultant hereby assigns fully (and agrees to further assign or cause to be assigned, as necessary to
effect such full assignment) to the Company all Inventions and any copyrights, patents, or other intellectual property rights relating thereto. 
 (b) Further Assurances. Consultant agrees to assist the Company, or its designee, at the Company’s expense, in every proper way to secure the Company’s rights in the Inventions and any
copyrights, patents, or other intellectual property rights relating thereto in any and all countries, including in the disclosure to the Company of all pertinent information and data with respect thereto, the execution of all applications,
specifications, oaths, assignments and all other instruments that the Company shall deem necessary in order to apply for and obtain such rights and in order to assign and convey to the Company, its successors, assigns and nominees the sole and
exclusive right, title and interest in and to such Inventions, and any copyrights, patents, or other intellectual property rights relating thereto. Consultant further agrees that consultant’s obligation to execute or cause to be executed any
such instrument or papers, when it is in Consultant’s power to do so, shall continue after the termination of this Agreement. 
 (c) Pre-Existing Materials. Consultant agrees that if, in the course of performing the Services, Consultant incorporates into any Invention developed hereunder any invention, improvement,
development, concept, discovery or other proprietary information owned by Consultant or in which consultant has an interest (i) Consultant shall inform the company, in writing, before incorporating such invention, improvement, development,
concept, discovery or other proprietary information into any Invention; and (ii) the Company is hereby granted and shall have a nonexclusive, royalty-free, perpetual, irrevocable, worldwide transferable license (with the right to sublicense) to
make, have made, modify, use, sell and/or import such item as part of or in connection with such Invention. In addition, Consultant agrees that Consultant will promptly make full written disclosure to the company, will hold in trust for the sole
right and benefit of the Company, and hereby assigns to the Company, or its designees, all Consultant’s right, title and interest in and to any Inventions created within three years after the termination of this Agreement that are based upon or
derived from Confidential Information, and Consultant agrees that such Inventions are and shall be the sole and exclusive property of the Company. Nothing in the preceding sentence shall be construed to limit Consultant’s obligations under
Section 2 (“Confidentiality”) of this Agreement. Consultant shall not incorporate any invention, improvement development, concept, discovery or other proprietary information owned by any third party into any Invention without
Company’s prior written permission. 

 (d) Attorney in Fact. Consultant agrees that if the Company is unable, because of
Consultant’s unavailability, dissolution, mental or physical incapacity, or for any other reason, to secure Consultant’s signature to apply for or to pursue any application for any United States or foreign jurisdiction’s patents or
copyright registrations covering the Inventions assigned to the Company above, then Consultant hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as Consultant’s agent and attorney in fact, to act
for and in consultant’s behalf and stead to execute and file any such applications and to do all other lawfully permitted acts to further the prosecution and issuance of patents, and copyright registrations with the same legal force and effect
as if executed by Consultant. 
  

	 	4.	NON-COMPETE AND NON-SOLICITATION 

 During the terms of Consultant’s engagement and for a period of three (3) years immediately following the termination or expiration of its engagement, consultant shall not directly or indirectly
(i) carry on any business or activity that competes directly or indirectly with the Company for a radius of fifth (50) miles from the present location of the Company in Austin, Texas; (ii) solicit or induce any employee or consultant
of the Company to quit their employment or cease doing business with the Company, or (iii) solicit any actual or potential customer of the Company for any business that competes directly or indirectly with the Company, unless Consultant is
specifically authorized to do (i), (ii) or (iii) with the prior written consent of the Company. Consultant acknowledges that the restrictions set forth in this Section 4 are reasonable and necessary for the proper fulfillment of its
consulting obligations. 
  

	 	5.	CONFLICTING OBLIGATIONS 

 Consultant certifies that Consultant has no outstanding agreement or obligation that is in conflict with any of the provision of this Agreement, or that would preclude Consultant from complying with the
provision hereof, and further certifies that consultant will not enter into any such conflicting agreement. 
  

	 	6.	TERM AND TERMINATION 

 (a) Term. This Agreement will commence on June 7, 2011 and will continue in full force and effect for an initial term of six (6) months. This Agreement may be renewed by the Parties, by
mutual written agreement. Termination. Either Party may termination this Agreement for any reason or no reason upon giving thirty (30) days prior written notice thereof to the other Party. Any such notice shall be addressed to the other
Party at the address shown below and shall be deemed given upon delivery if personally delivered, or forty-eight (48) hours after deposited in the United States mail, postage prepaid, registered or certified mail, return receipt requested.
Either Party may terminate immediately and without prior notice if the other Party is in breach of any material provision of this Agreement, but such termination shall not preclude ay other legal or equitable remedy available to the terminating
Party. 

 (b) Survival. Upon termination of this Agreement, all rights and duties of the
Parties toward each other shall cease except that: 
 (i) the Company shall be obliged to pay, within thirty (30) days of
the effective date of termination, any amounts owing to Consultant for expenses, if any, in accordance with the provision of Section 1 (“Services and Consideration”) hereof; and 

(ii) Sections 2 (“Confidentiality”), 3 (“Ownership”), 4 (“Non-Compete and Non-Solicitation”) and 7
(“Independent Contractors”), Section 9 (“Arbitration and Equitable Relief”) and such other provision that by their terms extend shall survive termination of this Agreement. 

 

	 	7.	ASSIGNMENT 

Neither this Agreement nor any right hereunder or interest herein may be assigned or transferred by Consultant without the express written
consent of the Company. 
  

	 	8.	INDEPENDENT CONTRACTOR 

 The express intention of the Parties is that Consultant is an independent contractor to the Company hereunder. Nothing in this Agreement shall in any way be construed to constitute Consultant as an agent,
employee or representative of the Company, but Consultant shall perform the Services hereunder as an independent contractor. Consultant agrees to furnish (or reimburse the Company for) all tools and materials necessary to accomplish this Agreement,
and shall incur all expenses associated with performance without reimbursement from the Company, except as expressly provided herein. Consultant acknowledges and agrees that Consultant is obligated to report as income to all applicable taxing
authorities all compensation receive by Consultant pursuant to this Agreement, and Consultant agrees to and acknowledges the obligation to pay all self-employment and other taxes thereon. Consultant further agrees to indemnify and hold harmless the
Company and its directors, officers, and employees from and against all taxes, losses, damages, liabilities, costs and expenses, including attorney’s fees and other legal expenses, arising directly or indirectly from (i) any negligent,
reckless or intentionally wrongful act of Consultant or Consultant’s assistants, employees or agents, (ii) a determination by a court or agency that the Consultant is not an independent contractor, or (iii) any breach by the
Consultant or Consultant’s assistants, employees or agents of any of the covenants contained in this Agreement. 
  

	 	9.	BENEFITS 

Consultant acknowledges and agrees and the Parties’ intent hereunder is that Consultant receive no Company-sponsored benefits from
the Company either as a Consultant or an employee. Such benefits include, but are not limited to, paid vacation, sick leave, medical insurance, and 401(k) participation. If Consultant is reclassified by a state or federal agency or court as any
employee, the Company may elect to have Consultant become a reclassified employee, receiving no benefits except those mandated by state or federal law, even if by the terms of the Company’s standard benefit plans in effect at the time of such
reclassification Consultant would otherwise be eligible for such benefits. 

	 	10.	ARBITRATION AND EQUITABLE RELIEF 

 (a) Disputes. Except as provided in Section 10(d) below, the Company and Consultant agree that any dispute or controversy arising out of, relating to or in connection with the interpretation,
validity, construction, performance, breach or termination of this Agreement shall be settled by binding arbitration to be held in Austin, Texas in accordance with the Commercial Arbitration Rules, supplemented by the Supplemental Procedures for
Large Complex Disputes, of the American Arbitration Association as then in effect (the “Rules”). The arbitrator may grant injunctions or other relief in such disputes or controversy. The decision of the arbitrator shall be final,
conclusive and binding on the Parties to the arbitration. Judgment may be entered on the arbitrator’s decision in any court of competent jurisdiction. 
 (b) Consent to Personal Jurisdiction. The arbitrator(s) shall apply Texas law to the merits of any dispute or claim, without reference to conflicts of law rules. Consultant hereby consents to the
personal jurisdiction of the state and federal courts in Texas for any action or proceeding arising from or relating to this Agreement or relating to any arbitration in which the Parties are participants. 

(c) Equitable Relief. The Parties may apply to any court of competent jurisdiction for a temporary restraining order, preliminary
injunction, or other interim or conservatory relief, as necessary, without breach of this arbitration provision and without abridgment of the powers of the arbitrator. Consultant further agrees, for the purposes of this Section 10(c) and
Section 10(a) of this Agreement, that any breach of the covenants set forth in Sections 2 (“Confidentiality”), 3 (“Ownership”) and 4 (“Non-Compete and Non-Solicitation”) of this Agreement would cause the company
irreparable injury for which it would not have an adequate remedy at law. Accordingly, consultant agrees that if Consultant breaches Section 2 (“Confidentiality”), 3 (“Ownership”), or 4 (“Non-Compete and
Non-Solicitation”) of this Agreement, the Company will be entitled, in addition to any other right or remedy available, to temporary or preliminary equitable relief (including, but not limited to, a temporary restraining order or a preliminary
injunction) from a court of competent jurisdiction restraining such breach or threatened breach and final and permanent equitable relief (including, but not limited to, the granting of a permanent injunction and the ordering of specific performance)
from the arbitrator restraining such breach or threatened breach. 
 (d) Acknowledgment. CONSULTANT HAS READ AND
UNDERSTANDS SECTION 10 (“ARBITRATION AND EQUITABLE RELIEF”), WHICH DISCUSSES ARBITRATION. CONSULTANT UNDERSTANDS THAT BY SIGNING THIS AGREEMENT, CONSULTANT AGREES TO SUBMIT ANY CLAIMS ARISING OUT OF, RELATING TO, OR IN CONNECTION WITH THIS
AGREEMENT, OR THE INTERPRETATION, VALIDITY, CONSTRUCTION, PERFORMANCE, BREACH OR TERMINATION THEREOF, TO BINDING ARBITRATION, EXCEPT AS PROVIDED IN SECTION 10(c), AND THAT THIS ARBITRATION CLAUSE CONSTITUTES A WAIVER OF CONSULTANTS RIGHT TO A JURY
TRIAL AND RELATES TO THE RESOLUTION OF ALL DISPUTES RELATING TO ALL ASPECTS OF THE RELATIONSHIP BETWEEN THE PARTIES. 

	 	11.	GOVERNING LAW 

This Agreement shall be governed by the internal substantive laws, but not the choice of law rules, of the state of Texas. 

 

	 	12.	ENTIRE AGREEMENT 

This Agreement is the entire agreement of the Parties and supersedes any prior agreements between them, whether written or oral, with
respect to the subject matter hereof. No waiver, alteration, or modification of any of the provisions of this Agreement shall be binding unless in writing and signed by duly authorized representatives of the Parties hereto. 

 

	 	13.	ATTORNEY’S FEES 

 In any court action at law or equity that is brought by one of the Parties to enforce or interpret the provisions of this Agreement, the prevailing party will be entitled to reasonable attorney’s
fees, in addition to any other relief to which that party may be entitled. 
  

	 	14.	SEVERABILITY 

 If
one or more of the provisions in this Agreement are deemed void by law, then the remaining provisions will continue in full force and effect. 
  

	 	15.	TITLES AND SUBTITLES 

 The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 

IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the day and year first above written. 

 

									
		 		 		 	 VERMILLION, INC.

Building Three, Suite 100
 Austin TX
78731

					
	By:	 	 /s/ Bruce A. Huebner
	 		 	By:	 	 /s/ Gail S. Page

									
					
	Name: Title: Date:	 	 Bruce A. Huebner

Consultant
 June 17, 2011
	 		 	Name: Title: Date:	 	 Gail S. Page
 Chief
Executive Officer
 June 17, 2011

 Exhibit A 

 

	1.	Description of Services: 

Consultation focused on the Commercial Operations and Corporate Strategy 

 

	2.	Compensation 

  

	 	•	 	 The Company will pay Consultant at the rate of $200 per hour for the Services, not to exceed $1600 per day. 

 

	 	•	 	 The Company will reimburse Consultant for all approval reimbursable travel expenses as provided in Section 1(b).

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00193-of-00352.parquet"}]]